Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mederma correction

This article was originally published in The Rose Sheet

Executive Summary

A story that ran in the July 20 issue of "The Rose Sheet" wrongly identified anti-scarring as a $30 mil. market opportunity. According to Merz Pharmaceuticals, which recently launched Mederma Stretch Marks Therapy, the market for stretch-mark treatments is worth $30 mil., while the larger anti-scarring business is valued at roughly $55 mil. "The Rose Sheet" regrets the error. Also, to be clear, the "roughly half of women" who have been "dissatisfied" with products formulated to reduce the appearance of stretch marks were polled before Mederma Stretch Marks Therapy became available to them
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS016333

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel